Skip to main content

23.04.2024 | Case Report

Simultaneous occurrence of autoimmune hepatitis and autoimmune hemolytic anemia after COVID-19 infection: case report and literature review

verfasst von: Ryo Abe, Naoyuki Hasegawa, Satoshi Suzuki, Sakiko Shigeta, Ryota Matsuoka, Takayasu Kato, Yusuke Niisato, Emiko Seo, Daisuke Matsubara, Kiichiro Tsuchiya

Erschienen in: Clinical Journal of Gastroenterology

Einloggen, um Zugang zu erhalten

Abstract

Various autoimmune diseases have been reported to develop as a result of a coronavirus disease 19 (COVID-19) infection. There have been some reports of COVID-19-triggered autoimmune hepatitis and autoimmune hemolytic anemia infection, but none have reported simultaneous onset of these diseases. A 15-year-old girl was admitted to our hospital with severe liver injury and anemia. Three weeks before admission, her father was diagnosed with COVID-19, after which she became aware of a sore throat. Two weeks later, she visited her doctor for malaise. She was referred to our hospital due to severe anemia, elevated hepatobiliary enzymes, and jaundice. A COVID-19 polymerase chain reaction test was positive at the time of referral. She was diagnosed with autoimmune hemolytic anemia based on decreased hemoglobin and haptoglobin, positive direct Coombs test, and increased urinary urobilinogen. Blood tests were positive for antinuclear antibodies, and a liver biopsy revealed interface hepatitis and plasma cell infiltration, consistent with autoimmune hepatitis. Based on these findings, a diagnosis of autoimmune hepatitis and autoimmune hemolytic anemia triggered by COVID-19 infection was made. Steroid therapy was initiated, which resulted in rapid improvement of blood markers and symptoms.
Literatur
1.
3.
Zurück zum Zitat Sgamato C, Rocco A, Compare D, et al. Autoimmune liver diseases and SARS-CoV-2. World J Gastroenterol. 2023;29:1838–51.CrossRefPubMedCentral Sgamato C, Rocco A, Compare D, et al. Autoimmune liver diseases and SARS-CoV-2. World J Gastroenterol. 2023;29:1838–51.CrossRefPubMedCentral
5.
Zurück zum Zitat Andres L, Badia E, Fernandez C, et al. Autoimmune hepatitis. Another consequence of COVID-19? Gastroenterol Hepatol. 2023;46:135–6. Andres L, Badia E, Fernandez C, et al. Autoimmune hepatitis. Another consequence of COVID-19? Gastroenterol Hepatol. 2023;46:135–6.
6.
Zurück zum Zitat Singh B, Kaur P, Maroules M. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome triggered by COVID-19. Eur J Case Rep Intern Med. 2021;8: 002264.PubMedPubMedCentral Singh B, Kaur P, Maroules M. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome triggered by COVID-19. Eur J Case Rep Intern Med. 2021;8: 002264.PubMedPubMedCentral
7.
Zurück zum Zitat Cunha-Silva M, de Franca EVC, Greca RD, et al. Autoimmune hepatitis and primary biliary cholangitis overlap syndrome after COVID-19. Autops Case Rep. 2023;13: e2023422.CrossRefPubMedPubMedCentral Cunha-Silva M, de Franca EVC, Greca RD, et al. Autoimmune hepatitis and primary biliary cholangitis overlap syndrome after COVID-19. Autops Case Rep. 2023;13: e2023422.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Algassim AA, Elghazaly AA, Alnahdi AS, et al. Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. Ann Hematol. 2021;100:37–43.CrossRefPubMed Algassim AA, Elghazaly AA, Alnahdi AS, et al. Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. Ann Hematol. 2021;100:37–43.CrossRefPubMed
10.
Zurück zum Zitat Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:928–38.CrossRef Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:928–38.CrossRef
11.
Zurück zum Zitat Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol. 2011;8:320–9.CrossRefPubMed Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol. 2011;8:320–9.CrossRefPubMed
12.
Zurück zum Zitat Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–8.CrossRefPubMed Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–8.CrossRefPubMed
13.
Zurück zum Zitat Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224–31.CrossRefPubMed Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224–31.CrossRefPubMed
14.
16.
Zurück zum Zitat Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667–78.CrossRefPubMedPubMedCentral Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667–78.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Turgutkaya A, Bolaman AZ, Yavasoglu I. COVID-19-associated Evans syndrome: a case report and review of the literature. Transfus Apher Sci. 2022;61: 103339.CrossRefPubMed Turgutkaya A, Bolaman AZ, Yavasoglu I. COVID-19-associated Evans syndrome: a case report and review of the literature. Transfus Apher Sci. 2022;61: 103339.CrossRefPubMed
18.
Zurück zum Zitat Abe M, Mashiba T, Zeniya M, et al. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011;46:1136–41.CrossRefPubMed Abe M, Mashiba T, Zeniya M, et al. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011;46:1136–41.CrossRefPubMed
19.
Zurück zum Zitat Iijima S. Pitfalls in the serological evaluation of maternal cytomegalovirus infection as a potential cause of fetal and neonatal involvements: a narrative literature review. J Clin Med. 2022;11:5006.CrossRefPubMedPubMedCentral Iijima S. Pitfalls in the serological evaluation of maternal cytomegalovirus infection as a potential cause of fetal and neonatal involvements: a narrative literature review. J Clin Med. 2022;11:5006.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Syed U, Subramanian A, Wraith DC, et al. Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care. BMC Med. 2023;21:363.CrossRefPubMedPubMedCentral Syed U, Subramanian A, Wraith DC, et al. Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care. BMC Med. 2023;21:363.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Chang R, Chen TYT, Wang SI, et al. Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine. 2023;56: 101783.CrossRefPubMedPubMedCentral Chang R, Chen TYT, Wang SI, et al. Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine. 2023;56: 101783.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Root-Bernstein R. From co-infections to autoimmune disease via hyperactivated innate immunity: COVID-19 autoimmune coagulopathies, autoimmune myocarditis and multisystem inflammatory syndrome in children. Int J Mol Sci. 2023;24:3001.CrossRefPubMedPubMedCentral Root-Bernstein R. From co-infections to autoimmune disease via hyperactivated innate immunity: COVID-19 autoimmune coagulopathies, autoimmune myocarditis and multisystem inflammatory syndrome in children. Int J Mol Sci. 2023;24:3001.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671–722.CrossRefPubMed Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671–722.CrossRefPubMed
Metadaten
Titel
Simultaneous occurrence of autoimmune hepatitis and autoimmune hemolytic anemia after COVID-19 infection: case report and literature review
verfasst von
Ryo Abe
Naoyuki Hasegawa
Satoshi Suzuki
Sakiko Shigeta
Ryota Matsuoka
Takayasu Kato
Yusuke Niisato
Emiko Seo
Daisuke Matsubara
Kiichiro Tsuchiya
Publikationsdatum
23.04.2024
Verlag
Springer Nature Singapore
Erschienen in
Clinical Journal of Gastroenterology
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-024-01972-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.